Ivrea 12mg Tablet DT contains Ivermectin 12mg, an antiparasitic agent indicated for the treatment of various parasitic infections. Ivermectin belongs to the class of macrocyclic lactones and exerts its effect by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization, paralysis, and death of the parasite. Ivrea 12mg Tablet DT is primarily used for the management of onchocerciasis (river blindness), strongyloidiasis, and other susceptible parasitic infestations. The tablet is designed as a dispersible tablet, facilitating ease of administration and improving patient compliance, especially in populations with swallowing difficulties. Ivrea should be administered as a single dose or as prescribed by the healthcare provider, with dosing based on body weight and the specific parasitic infection being treated. It is essential to follow medical advice regarding dosage and duration to ensure efficacy and minimize the risk of resistance. Common adverse effects may include dizziness, headache, nausea, and mild gastrointestinal disturbances, which are generally transient. Ivrea 12mg Tablet DT should be used cautiously in patients with hepatic impairment and is contraindicated in individuals with known hypersensitivity to ivermectin or any excipients. Pregnant and lactating women should use this medication only if clearly needed and under medical supervision.